Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C. Chalmers SA, et al. Among authors: klein e. Clin Immunol. 2018 Dec;197:205-218. doi: 10.1016/j.clim.2018.10.008. Epub 2018 Oct 16. Clin Immunol. 2018. PMID: 30339790 Free PMC article.
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T, Steffgen J, Benediktus E, Müller F, Schultz A, Klein E, Ramanujam M, Harcken C, Gupta A, Wu J, Wiebe S, Li X, Flack M, Padula SJ, Visvanathan S, Hünnemeyer A, Hui J. Litzenburger T, et al. Among authors: klein e. Br J Clin Pharmacol. 2021 Apr;87(4):1824-1838. doi: 10.1111/bcp.14571. Epub 2020 Nov 20. Br J Clin Pharmacol. 2021. PMID: 32986868 Free PMC article. Clinical Trial.
N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.
Abeywardane A, Caviness G, Choi Y, Cogan D, Gao A, Goldberg D, Heim-Riether A, Jeanfavre D, Klein E, Kowalski JA, Mao W, Miller C, Moss N, Ramsden P, Raymond E, Skow D, Smith-Keenan L, Snow RJ, Wu F, Wu JP, Yu Y. Abeywardane A, et al. Among authors: klein e. Bioorg Med Chem Lett. 2016 Nov 1;26(21):5277-5283. doi: 10.1016/j.bmcl.2016.09.047. Epub 2016 Sep 21. Bioorg Med Chem Lett. 2016. PMID: 27692854 Free article.
Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Nguyen JK, et al. Among authors: klein ea. Histopathology. 2024 Jun 3. doi: 10.1111/his.15231. Online ahead of print. Histopathology. 2024. PMID: 38828674
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, Pigneux A, Récher C, Largeaud L, Bertoli S. Gondran C, et al. Among authors: klein e. Blood Cancer J. 2024 May 31;14(1):91. doi: 10.1038/s41408-024-01069-9. Blood Cancer J. 2024. PMID: 38821940 Free PMC article.
3,455 results